Topics:

Pharmion Purchases Cabrellis, US Developer of Amrubicin

Pharmion Purchases Cabrellis, US Developer of Amrubicin

BOULDER, Colorado—Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.